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Relaxin-3 is the most recently discovered member of the relaxin
family of peptide hormones. In contrast to relaxin-1 and -2, whose
main functions are associated with pregnancy, relaxin-3 is involved in
neuropeptide signaling in thebrain.Here,wereport the solutionstruc-
ture of human relaxin-3, the first structure of a relaxin familymember
tobe solvedbyNMRmethods.Overall, relaxin-3adopts an insulin-like
fold, but the structure differs crucially from the crystal structure of
human relaxin-2 near the B-chain terminus. In particular, the B-chain
C terminus folds back, allowing TrpB27 to interact with the hydropho-
biccore.This interactionpartlyblocks theconservedRXXXRXXImotif
identifiedasadeterminant for the interactionwith therelaxinreceptor
LGR7 and may account for the lower affinity of relaxin-3 relative to
relaxin for this receptor. This structural feature is likely important for
the activation of its endogenous receptor, GPCR135.
Recent developments have caused considerable excitement in the
relaxin field, including the discovery of a new member of the relaxin
family, relaxin-3 (1), and the identification of several long sought after
relaxin receptors (2). Prior to the discovery of the relaxin-3 gene (RLN3),
only one relaxin gene had been characterized in most mammals, with
the exception of humans and higher primates, in which two separate
genes, RLN1 and RLN2, were known (3, 4). The product of the human
RLN2 gene, human relaxin-2 (H2 relaxin), is the functional ortholog of
the RLN1 gene product from non-primate species, which is termed
relaxin. The function of the product of the human RLN1 gene, human
relaxin-1 (H1 relaxin), is unknown; and indeed, a native H1 relaxin
peptide has not been isolated (5). Hence, throughout this work, “relaxin”
will refer to the pregnancy hormones H2 relaxin and non-primate
relaxin. Relaxin-3 is the ancestor of the entire relaxin peptide family (5),
and RLN3 genes have been identified in all mammalian genomes as well
as in the genomes of chicken, frog, and various fish species. In contrast,
the RLN1 gene is found only in mammals. Fig. 1 shows a sequence
comparison of the product of the human RLN3 gene, human relaxin-3
(H3 relaxin); H2 and H1 relaxins; and relaxin-3 orthologs from other
species. Interestingly, the relaxin-3 sequences are highly conserved
between species, in contrast to relaxin, which shows considerable
sequence variation.
Relaxin has long been regarded as a hormone mainly associated with
pregnancy. Produced in the corpus luteum and/or placenta of most
mammals, it has numerous pregnancy-specific actions, including the
remodeling of the reproductive tract and preparation of the mammary
apparatus for lactation (6). However, relaxin also has important physi-
ological roles outside of pregnancy. It inhibits collagen biosynthesis and
promotes collagen breakdown (7–9) and causes vasodilatation in vari-
ous tissues (10). Interestingly, the expression pattern of relaxin-3 differs
significantly from that of relaxin, suggesting a distinctly different phys-
iological role. The highest expression of relaxin-3 in all species exam-
ined to date, including humans, is in the brain. In rats (11) and mice (1),
the expression is localized to a specific region of the dorsal tegmental
region of the pons called the nucleus incertus. Anatomical studies sug-
gest that this nucleus is involved in amidbrain behavior control network
that influences circuits regulating locomotion, attention, and learning
processes and that responds to stress-related neuroendocrine signals
(12). Mapping studies have demonstrated that relaxin-3-immunoreac-
tive nerve fibers emanating from the nucleus incertus innervate numer-
ous regions of the brain, suggesting that the nucleus incertus utilizes
relaxin-3 as a neurotransmitter (13). These data, coupled with the
remarkable conservation of the relaxin-3 peptide from fish to humans,
suggest that relaxin-3 has highly important, but presently unknown,
central actions. Indeed, a very recent study suggests that relaxin-3 is
involved in appetite regulation (14), and another study has demon-
strated that relaxin-3 mRNA production is increased in response to
water-restraint stress (13), suggesting a role in the stress response.
Members of the relaxin family are structurally similar to insulin, com-
prising two peptide chains that are linked by two disulfide bonds, with
the A-chain containing a third, intrachain disulfide bond. However,
unlike insulin, whose receptor is a tyrosine kinase, members of the
relaxin peptide family bind to G-protein-coupled receptors (GPCRs).2
The first receptors identified responding to relaxin stimuli were the
leucine-rich repeat-containing GPCRs LGR7 and LGR8 (2), which both
have low nanomolar affinity for relaxin and which are capable of medi-
ating the actions of relaxin through a cAMP-dependent pathway (2).
Interestingly, relaxin-3 also activates LGR7, albeit with a lower affinity
than relaxin, but has a significantly reduced affinity for LGR8 (15).
Recent work has identified two additional orphan GPCRs, GPCR135
and GPCR142, which also respond to relaxin-3 activation (16, 17). On
the basis of the higher affinity of relaxin-3 for GPCR135 and their coex-
pression in regions of the brain, it was concluded that relaxin-3 is the
endogenous ligand forGPCR135, whereas the primary ligands for LGR8
and GPCR142 are two other members of the relaxin peptide family,
INSL3 (insulin-like peptide-3 or Leydig insulin-like peptide) (18) and
INSL5 (insulin-like peptide-5) (19), respectively. The cross-reactivity of* This work was supported in part by National Health and Medical Research Council
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these hormone-receptor signaling systems has raised questions about
which factors are responsible for the selectivity of these ligand-receptor
pairings. Moreover, as relaxin-3, GPCR135, and LGR7 are all expressed
in the brain, understanding the significance of the interaction of relax-
in-3 with LGR7 will be crucial in determining its function.
In this study, we provide a crucial piece of the puzzle by presenting
the solution structure of the human form of the most recently discov-
ered member of this hormone family, relaxin-3. The structure reveals a
relaxin/insulin fold, but with an unusual conformation of the C-termi-
nal region of the B-chain. The structural data provide insights into the
receptor specificities of this new member of the relaxin peptide family.
EXPERIMENTAL PROCEDURES
Peptide Synthesis—The A- and B-chains were assembled as C-termi-
nal peptide acids or amides by Fmoc (N-(9-fluorenyl)methoxycarbonyl)
solid-phase synthesis on a hydroxymethylphenoxyacetyl- or 5-(4-ami-
nomethyl-3,5-dimethoxyphenoxy)valeryl-polyethylene glycol/polysty-
rene support using the following selective cysteine S-protection:
CysA10/A15, trityl; CysA11/B11, acetamidomethyl; CysA24, t-butyl; and
CysB22, trityl. Following conventional trifluoroacetic acid cleavage in the
presence of scavengers, the intramolecular disulfide bond of the
A-chain was formed by aeration, and CysA24 (t-butyl) was displaced
with S-pyridinyl by reaction with 2,2-dipyridyl disulfide in triflu-
oromethanesulfonic acid. Combination of the peptide with the B-chain
occurred by thiolysis, after which the third and final disulfide bond
betweenA11 and B10was formed by iodolysis. The purity of the peptide
was confirmed by MALDI-TOF mass spectrometry (for example, pep-
tide acid: theory, 5500.5; and found, 5499.6) and analytical reversed-
phase HPLC.
Biological Activity Assays—H3 relaxin acid and amide were tested for
their ability to activate LGR7, LGR8, and GPCR135. Stably transfected
human embryonic kidney 293T cells expressing human LGR7 or LGR8
(15) and Chinese hamster ovary K1 cells stably expressing human
GPCR135 (20) were stimulated for 30 min with various concentrations
of H3 relaxin acid or amide. LGR7 and LGR8were tested in parallel with
H2 relaxin and human INSL3, respectively (both at 100 nM), and
GPCR135 with forskolin (5 M) to determine maximum cellular cAMP
response. cAMP accumulationwasmeasured in cell lysates as described
previously (15).
NMR Spectroscopy—Pulsed-field gradient NMR diffusion experi-
ments were performed with a two-dimensional sequence using stimu-
lated echo longitudinal encode-decode (21). The lengths of all pulses
and delays were held constant, and 32 spectra were acquired with the
strength of the diffusion gradient varying between 2 and 95% of its
maximum value. The lengths of the diffusion gradient and the stimu-
lated echo were optimized for each sample to give a total decay in the
protein signal of 90%. Dioxane was added to the samples to a final
concentration of 0.2 mM and used as an internal standard (22). Samples
prepared for structure determination contained 1 mM peptide dis-
solved in 90% H2O and 10 or 100% (v/v) D2O at pH 3.0. Spectra were
recorded at 290, 298, and 303 K on a Bruker Avance 600-MHz spec-
trometer or on a Bruker DMX 750-MHz spectrometer. Two-dimen-
sional experiments recorded included double-quantum filtered COSY;
total correlation spectroscopy using an MLEV-17 spin lock sequence
with a mixing time of 80 ms; and nuclear Overhauser effect (NOE)
correlation spectroscopy with mixing times of 100, 150, and 200 ms.
Spectra were generally acquired with 4096 complex data points in F2
and 512 increments in the F1 dimension over a spectral width of 14 ppm.
Slowly exchanging NH protons were detected by acquiring a series of
one-dimensional and total correlation spectra of the fully protonated
peptide immediately after dissolution in D2O. As most amides disap-
peared within the first 2 h, resonances still visible after 2 h were consid-
ered to be protected from the solvent by hydrogen bonding. Spectra
were processed on a SiliconGraphicsOctaneworkstation usingXWIN-
NMR (Bruker BioSpin Corp.). The F1 dimension was generally zero-
filled to 1024 real data points, and 90° phase-shifted sine bell window
functions were applied before Fourier transformation. Chemical shifts
were referenced to 2,2-dimethyl-2-silapentanesulfonic acid at 0.00 ppm.
Distance restraints were derived primarily from a 100-ms NOE cor-
relation spectrum recorded at 298 K and 600 MHz. Cross-peaks were
assigned and integrated in XEASY and converted to distance restraints
using CYANA. Distance restraints for cross-peaks that could not be
unambiguously assigned were introduced into structure calculations as
ambiguous restraints. Backbone dihedral restraints were inferred from
3JNH-H coupling constants. Because of the generally broad lines of
many amide protons, coupling constants were, in some cases, estimated
from a combination of apparent coupling constants, peak intensities,
and consistency with preliminary structures. The dihedral angle  was
restrained to 120  40° for 3JNH-H  8 Hz and to 60  30° for
3JNH-H  5 Hz. Additional  angle restraints of 100  80° were
included where a positive angle could be excluded based on a strong
sequential Hi1-HNi NOE compared with the intraresidue Hi-HNi
NOE. Side chain 1 angles and stereospecific assignments were deter-
mined on the basis of observed NOE and 3JH-H coupling patterns. For
a predicted t2g3 side chain conformation, the 1 angles were restrained
to60 30° (residuesTrpA13, GluA19, CysA24, ArgB8, LeuB9, CysB10, and
CysB22); and for a g2t3 conformation, the angles were constrained to
180  30° (residues LysA12, LysA17, LeuA23, PheB14, and ArgB26). No
residues could be confirmed to be in the g2g3 conformation based on
experimental data. Additional stereospecific assignments of the methyl
groups for ValB18 and LeuA23 were determined based on their NOE
patterns. Hydrogen bonds were included in the structure calculations
for all amide protons concluded to be slowly exchanging only after a
suitable acceptor could be identified in the preliminary structures. In all
cases, these hydrogen bonds were found between the backbone atoms
within the elements of secondary structure. Three-dimensional struc-
tures were calculated using simulated annealing and energy minimiza-
tion protocols from ARIA (23) in the program CNS (24). The protocol
FIGURE 1. Sequence alignment of H3 relaxin
(boxed) with H1 and H2 relaxins and relaxin-3
orthologs from other species. Conserved resi-
dues are indicated in single-letter amino acid
codes, and conservative changes are marked with
plus signs. The conserved cysteine residues
shaded, and their connectivities indicated by
brackets. The characteristic relaxin binding motif
RXXXRXX(I/V) is shaded and marked with asterisks.
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involves a high temperature phase with 4000 steps of 0.015 ps of torsion
angle dynamics; a cooling phase with 4000 steps of 0.015 ps of torsion
angle dynamics during which the temperature is lowered to 0 K; and
finally, an energy minimization phase with 5000 steps of Powell mini-
mization. The refinement in explicit water involves the following steps:
heating to 500 K via steps of 100 K, each with 50 steps of 0.005 ps of
Cartesian dynamics; 2500 steps of 0.005 ps of Cartesian dynamics at 500
K; and a cooling phase in which the temperature is lowered in steps of
100 K, each with 2500 steps of 0.005 ps of Cartesian dynamics. Finally,
the structures were minimized with 2000 steps of Powell minimization.
Protein structures were analyzed using PROMOTIF and PRO-
CHECK and displayed using MOLMOL. Ramachandran analysis
showed that 83%of the residues are in themost favored regions, with the
remaining in the additionally allowed (15%) and generously allowed
(2%). The coordinates representing the solution structure of H3 relaxin
and the experimental restraints have been submitted to the ProteinData
Bank (Code 2FHW).
RESULTS
Peptide Synthesis—H3 relaxin was prepared as both its C-terminal
acid and amide forms by solid-phase peptide synthesis of the separate
A- and B-chains together with regioselective disulfide bond formation
(25). Chemical characterization by reversed-phase HPLC and MALDI-
TOF mass spectrometry confirmed the homogeneity of the products.
Tryptic mapping followed byMALDI-TOFmass spectrometry showed
that the disulfide bonds were in the correct insulin-like pairings.
Biological Activity—H3 relaxin acid was tested for its ability to stim-
ulate human LGR7, LGR8, and GPCR135 in parallel with the H3 relaxin
amide peptide. As shown in Fig. 2, the activities of the peptides were
identical. In LGR7-expressing cells, both peptides stimulated cAMP
accumulation to levels similar to those achieved with H2 relaxin (H3
relaxin acid pEC50 8.08 0.07 (n 4) andH3 relaxin amide pEC50
8.19  0.078 (n  3)). In GPCR135-expressing cells, both peptides
decreased forskolin-stimulated cAMP accumulation (H3 relaxin acid
pEC50  9.30  0.082 (n  3) and H3 relaxin amide pEC50  9.25 
0.092 (n 3)). Both peptides were unable to stimulate cAMP accumu-
lation in LGR8-expressing cells at concentrations up to 1 M (data not
shown).
NMR Diffusion Measurements—In light of the tendency of members
of the insulin superfamily to aggregate, includingH2 relaxin and insulin,
it was important to establish whether any multimers of H3 relaxin were
present under the conditions used for the NMR studies. This was
assessed by measuring translational diffusion using pulsed-field gradi-
ent experiments with dioxane (hydrodynamic radius of 2.12 Å) as an
internal standard. No significant difference in the hydrodynamic radius
of H3 relaxin was observed between concentrations of 0.1 and 1 mM
(14.2and14.4Å,respectively),indicatingthattherewasnoconcentration-
dependent aggregation. On the basis of the equation derived byWilkins
et al. (22) (Rh  (4.75  1.11)N0.290.02, where N is the number of
residues in the protein and Rh is the hydrodynamic radius in Ang-
stroms), the expected values for a H3 relaxin monomer (51 residues)
and a H3 relaxin dimer (102 residues) would be 14.8 and 18.2 Å,
respectively, confirming that H3 relaxin is monomeric under the con-
ditions used for these studies.
NMR Assignments and Structure Determination of H3 Relaxin—For
the structural analysis of H3 relaxin, extensive two-dimensional NMR
spectral data were recorded at 600 and 750MHz on a sample containing
1 mM peptide. The spectral data were of high quality with excellent
signal dispersion indicative of a well structured peptide. Resonance
assignments were achieved using two-dimensional sequential assign-
ment strategies, which, after analysis of spectra of both the H3 relaxin
acid and amide forms at several temperatures, resulted in complete
assignments for the peptide backbone and nearly complete assignment
for side chain resonances. Interestingly, a number of residues showed
broad lines; and in particular, significant line broadening was observed
for a set of resonances, including SerA7, CysA10, CysA11, ArgA12, TrpA13,
GlyA14, CysA15, CysB10, and PheB14, suggesting that conformational
exchange is present in this region of the molecule. This exchange is
likely a result of a pro-R/pro-S reorientation of one of the CysA10–
CysA15 or CysA11–CysB10 disulfide bonds. In addition, several weak spin
systems arising from a minor conformation were identified. These res-
onances were found to correspond to the N-terminal region of the
B-chain, i.e. AlaB2, AlaB3, ProB4, and TyrB5, and analysis of NOEs
revealed that they were the result of a cis/trans-isomerization of ProB4.
The trans-conformation is the major isomer (90%), with the cis-con-
formation corresponding to a minor conformation (10%), as evident
from strong sequential Hi1-Hi and Hi1-Hi NOEs, respectively.
The structural restraints derived from the NMR data and used for
structure calculations were based exclusively on data recorded for the
native acid form and included interproton distances, backbone and side
chain dihedral angles derived from coupling constants, and restraints
for hydrogen bonds deduced from amide exchange experiments. Struc-
tures were calculated by simulated annealing followed by refinement
and energy minimization in explicit solvent (H2O). Distance restraints
were derived from intensities of NOE cross-peaks in an NOE correla-
tion spectrum recorded at 298 K with a mixing time of 100 ms. As
expected for a 51-amino acid peptide, a number of cross-peaks were
ambiguous at the first stage of the assignment due to degeneracy of
chemical shifts, in particular in the methyl region. These ambiguities
were resolved using an iterative approach in which preliminary struc-
tures were used to guide the assignments and by inclusion of ambiguous
restraints. Hydrogen bonds were inferred from amide exchange behav-
ior and introduced into the structure calculations once the preliminary
structures indicated a suitable acceptor, which in all cases were found to
be within elements of secondary structure.
FIGURE 2. cAMP accumulation in response to H3 relaxin amide and acid in stably
transfected LGR7-expressing (a) and GPCR135-expressing (b) cells. Activities are
plotted as thepercentmaximumH2 relaxin- and forskolin-stimulated responses, respec-
tively. Stimulation of LGR7 resulted in increases in cellular cAMP, whereas stimulation of
GPCR135 resulted in decreases in cellular cAMP. The activities of the acid and amide
forms of the peptide were identical for both receptors.
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Description of the Three-dimensional Structure of H3 Relaxin—A
summary of the NMR data, including sequential and medium-range
NOEs, coupling constants, hydrogen exchange, and secondary H
shifts, is presented in Fig. 3. These data provide a good indication of the
presence of secondary structure, as both helical and extended confor-
mations have typical “fingerprints.” Helices are generally characterized
by a large number of medium-range NOE contacts, small 3JH-HN cou-
pling constants, and negative secondary shifts, whereas-sheets display
large 3JH-HN coupling constants and positive secondary shifts. The
exchange rates between the backbone amide protons and the solvent
can bemeasured by recording the decay in signal after dissolution of the
peptide in D2O and provide information about the presence of hydro-
gen bonds, as amide protons involved in hydrogen bonds are protected
from the solvent and display a slow exchange behavior. Although most
amides in H3 relaxin exchange in minutes, a number are still visible2
h after dissolution in D2O, and these could in all cases be correlated to
hydrogen bonds in the structure.
Fig. 4 shows a superposition of a family of 20 low energy structures
representing the solution structure of H3 relaxin. Overall, the structure
is well defined, with the exception of the N terminus of the B-chain,
which is disordered and likely flexible in solution. The energetic and
structural statistics for the structural family are summarized in Table 1.
All structures have good energies and covalent geometry as evident
from small deviations from ideal bond lengths and angles and the Ram-
achandran analysis, which showed that 83% of all non-Gly/Pro residues
are in the most favored regions and that the remaining residues, all of
which are in the more flexible regions of the peptide, are in the addi-
tionally allowed regions. It is clear that H3 relaxin adopts a typical relax-
in/insulin fold, with the A-chain containing two -helices (residues
A1–A13 and A17–A24) separated by a short -strand (residues A15–
FIGURE 3.SummaryofNMRdataonH3 relaxin.A, sequential andmedium-rangeNOEs observed in anNOE correlation spectrum recorded at 600MHzwith amixing timeof 100ms.
The thickness of the bars corresponds to the observed NOE intensities. B, coupling constants derived from double-quantum filtered COSY spectra. Downward pointing arrows
correspond to coupling constants5Hz, and upward pointing arrows correspond to coupling constants8Hz.C, amide exchange.Circles indicate amideprotons still visible 1 h after
dissolution in 100% D2O. D, secondary H shifts in ppm, i.e. observed H shifts minus random-coil shifts. Stretches of three or more positive or negative values are indicative of
extended or helical structure, respectively. E, elements of secondary structure in H3 relaxin as inferred from the above data and subsequent structure calculations.
FIGURE 4. Stereo viewof superimposition of the
family of 20 structures representing the solu-
tion structure of H3 relaxin. Selected residues
are labeled with chain identifiers and residue
numbers.
Structure of H3 Relaxin
5848 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281•NUMBER 9•MARCH 3, 2006
 at UQ Library on October 10, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
A17) and the B-chain containing a second -strand (residues B5–B7)
and an -helix (residues B12–B22). The A-chain helices lie parallel to
each other, forming a U-shaped arrangement. The B-chain helix is
placed across the face of the U, roughly perpendicular to the axes of the
A-chain helices. Enclosed between them is a significant hydrophobic
core involving the side chains of LeuA3, LeuA6, IleA20, LeuA23, CysA10,
CysA15, LeuB9, CysB10, PheB14, IleB15, ValB18, IleB19, and TrpB27. The
observation that the TrpB27 side chain interacts with the hydrophobic
core as evident from a large number of NOEs to CysA24, CysB22, IleB15,
ValB18, and IleB19 was surprising because, in the crystal structure of H2
relaxin, this region is disordered, and the Trp extends away from the
core, being fully exposed to the solvent. The interaction appears to have
become possible because of a shortening of the B-chain helix and a
reversal of the peptide backbone due to turns formed by the B23–B26
(GGSR) segment.
DISCUSSION
Solution Structure of H3 Relaxin—In this study, we have determined
the three-dimensional solution structure of H3 relaxin. H3 relaxin is
well behaved in solution and adopts an insulin-like fold that is braced by
the three disulfide bonds conserved throughout the family and that is
characterized by three helical segments and a short double-stranded
-sheet. Although the structure is well defined overall, there is evidence
for dynamic processes in several regions of the peptide. Most pro-
nounced is the disorder at the N terminus of the B-chain, which is likely
due to flexibility in this region. Supporting this suggestion is the obser-
vation of cis/trans-isomerization for ProB4, which results in two sets of
resonances for the amino acids in this region. A similar isomerization
has been observed in insulin (26), but there are no data suggesting that
this feature is implicated in the biological function. More interesting is
the observation of specific broadening of peaks from residues near the
CysA10–CysA15 and CysA11–CysB10 disulfide bonds, with the extreme
example being CysA10, which is broadened close to the limit of detec-
tion, suggesting conformational exchange on a microsecond time scale
in this region of the molecule. The most likely explanation for this is a
reorientation of the CysA10–CysA15 disulfide bond conformation as a
result of a 1 angle flip of one of the cysteines. Such a process has been
observed previously in disulfide-rich peptides, including, for example,
bovine pancreatic trypsin inhibitor (27, 28). In the H3 relaxin structural
family, equal populations of 60 and 180° 1 conformations of the
CysA15 side chain are observed, supporting the proposal that this disul-
fide can adopt more than one conformation. Although it is difficult to
correlate the two conformationswith other differences between the two
subpopulations of structures, the proximity of the CysA10–CysA15 disul-
fide bond to the side chain of PheB14 means that a reorientation of the
disulfide could cause a slight shift in the positioning of the aromatic ring.
This could result in turn in a large difference in the chemical shift of
neighboring protons between the two conformations due to the ring
current effects, whichwould explain the severe broadening observed for
the resonances around PheB14, including the CysA10–CysA15 disulfide
bond itself.
Amide exchange rates can provide information about the rigidity of a
structure in that amide protons involved in strong hydrogen bonds are
protected from exchange with the solvent. Among the amides found to
be slowly exchanging in H3 relaxin are all amides expected to be
involved in hydrogen bonds in the C-terminal -helix of the A-chain,
the -helix in the B-chain, and between the strands in the -sheet.
However, no slowly exchange amides were detected within the N-ter-
minal -helix in the A-chain despite a large number of medium-range
NOEs, confirming the presence of this -helix. On the basis of the fast
exchange rates, it appears that this -helix is more dynamic than the
other elements of secondary structure in H3 relaxin.
Comparison with the Structures of H2 Relaxin and Insulin—Struc-
tural studies of members of the insulin superfamily in solution have
been limited by the fact that both H2 relaxin and insulin form dimers or
higher aggregates in aqueous solution. High resolution crystal struc-
tures of the dimer of H2 relaxin (29) and zinc ion-stabilized insulin
hexamers (30–32) have been determined and provide a detailed pic-
tured of the molecular core and elements of secondary structure. How-
ever, the biologically active forms are the monomers, and the previous
structures do not provide a complete picture, as the dimer interface in
both cases involves the receptor-binding face, and it is unclear how the
formation of the dimer and crystal packing interactions may affect the
active site. In particular, there are questions about the conformation of
the C-terminal region of the B-chain, which in insulin forms a -strand
that hydrogen bonds in an intermolecular -sheet, whereas in H2
relaxin, this region appears to be disordered. To obtain structural data
on the insulin monomer and to investigate the determinants of the
aggregation, several mutants have been studied, most involving alter-
ation of the C terminus of the B-chain to remove hydrophobic interac-
tions in the dimer (33, 34).
Fig. 5 shows a comparison of the H3 relaxin NMR structure and the
x-ray structures of H2 relaxin and insulin, fromwhich it is clear that the
overall fold with the characteristic helical segments (residues A1–A13,
A17–A24, and B12–B22) is highly conserved and that the main differ-
ences are around the termini of the B-chain. The C-terminal tails of the
relaxins are shorter, comprising only five residues in H3 relaxin and six
residues in H2 relaxin compared with 11 residues in insulin. Although
this prevents the formation of a longer extended segment that can inter-
act both with the B-chain helix and with an additional monomer as in
insulin, we have shown here that the tail can still fold back to allow
interactions between TrpB27 and the hydrophobic core, mainly IleB19
and ValB18 in H3 relaxin. In contrast, in H2 relaxin, the helix is one turn
longer, including three additional helical hydrogen bonds, forcing the
tail to extend away from themolecular core. It is interesting to speculate
which differences in the primary sequence may be determinants of the
conformation of the C-terminal region. The tail is one residue longer in
H2 relaxin; but based on the structure of H3 relaxin, an additional res-
TABLE 1
NMR and refinement statistics for protein structures
H3 relaxin
NMR distance and dihedral constraints
Distance constraints
Total inter-residue NOEs 766
Sequential (i j 1) 311
Medium-range (i j 4) 213
Long-range (i j 5) 242
Hydrogen bonds 21
Total dihedral angle restraints
 33
1 16
Structure statistics
Violations (mean S.D.)
Distance constraints (0.2 Å) 0.4 0.60
Dihedral angle constraints (2°) 0
Maximum distance constraint
violation (Å)
0.24
Deviations from idealized geometry
Bond lengths (Å) 0.00414 0.00011
Bond angles 0.512 0.017°
Impropers 0.412 0.026°
Average pairwise r.m.s.d.a (Å)
Heavy 1.11
Backbone 0.50
a Pairwise root mean square deviation (r.m.s.d.) was calculated for 20 refined struc-
tures over residues A1–A24 and B3–B27.
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idue would not appear to interfere with the fold and is unlikely to pre-
vent such a conformation. Themain interaction between the tail and the
core in H3 relaxin involves hydrophobic contacts between the core and
the TrpB27 side chain; and as this Trp is conserved, similar interactions
would be possible in H2 relaxin. One possibility is that these hydropho-
bic interactionswould be destabilized by the substitution ofValB18 inH3
relaxin with GlnB18, which has a more polar side chain. Furthermore, in
H2 relaxin, the conformation in which the Trp side chain extends away
from the core is stabilized by hydrophobic interactions in a cluster com-
prising the side chains of TrpB27, MetB24, and MetA2. Neither of these
Met residues is conserved in H3 relaxin, which contains Ser and Gly in
the equivalent positions; and hence, such an interaction would not be
possible. The presence ofMetB24 inH2 relaxinwould also be expected to
have a stabilizing effect on the extended C-terminal helix, in contrast to
GlyB24 in H3 relaxin, which, together with its neighboring residues,
GlyB23 and SerB25, would be expected to be strongly helix-breaking.
Implications for Receptor Binding—The observation that, although
adopting a well defined structure, H3 relaxin is a rather dynamic mole-
cule is interesting, as studies on insulin have indicated that a significant
degree of flexibility is a requirement for binding to the insulin receptor.
In particular, an insulin mutant in which the fold was stabilized by the
addition of a peptide linker between the N terminus of the A-chain and
the C terminus of the B-chain was found to be biologically inactive,
despite adopting a native fold (35). In contrast, the des-PheB25 and PT
insulin mutants have also been studied by NMR and shown to have
significantly destabilized structures (34, 36). These conclusions were
based on increased amide exchange rates (34); and in the extreme case
of PT insulin, the co-solvent trifluoroethanol, known to stabilize helical
structures, had to be added to achieve a well defined structure in solu-
tion (36). Strikingly, both these molecules have increased biological
activity relative to native insulin (33, 37). Based on these observations, a
model for insulin binding to its receptor that involves both detachment
of the C-terminal part of the B-chain from the rest of the molecule and
unfolding of the N-terminal -helix has been proposed. Here, we have
shown that, in H3 relaxin, the amide exchange rates are also fast, in
particular in the N-terminal helix of the A-chain; and in addition, there
is evidence for line broadening as a result of conformational exchange
around this region. Although the relaxin and relaxin-3 receptors LGR7
FIGURE 5. A, comparison of H3 relaxin (left), H2
relaxin (middle; Protein Data Bank code 6RLX) (29),
andpig insulin (right; ProteinDataBank code4INS)
(40). Terminal residues and cysteines are labeled
with chain identifiers and residue numbers.
A-chain N- and C-terminal helices and the B-chain
helix are labeled 1, 2, and 3, respectively. B,
detailed comparison of the hydrophobic core of
H3 relaxin (left) and H2 relaxin (right). The fold is
stabilized by favorable interactions between the
side chains of Leu/TyrA3 (blue), LeuA6 (purple),
CysA10 (yellow), CysA15 (yellow), Ile/LeuA20
(orange), and Leu/PheA23 (green) of the A-chains
and Phe/LeuB14 (red), AlaB17 (green), and Val/
GlnB18 (cyan) of the B-chains of H3/H2 relaxin. In
addition, in H3 relaxin, the association of TrpB27
with the core extends the core to involve addi-
tional interactions with the side chains of IleB19
(light green), CysB22 (yellow), and CysA24 (yellow).
FIGURE 6. Comparison of the active sites of H3
relaxin (A) andH2relaxin (B).Bothpeptideshave
the RXXXRXX(I/V) motif shown to be crucial for the
interaction with LGR7; however, the C-terminal
conformation partly blocks the Ile side chain in H3
relaxin, which likely accounts for the lower affinity
for LGR7. A striking feature of H3 relaxin is the
highly exposedPheB20 (purple) on the same faceof
the B-chain helix. Being conserved throughout the
relaxin-3 family, it is likely that this Phe is involved
in the interaction with the relaxin-3 receptor and
important for the receptor specificity of relaxin-3.
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and GPCR135, respectively, are GPCRs and the insulin receptor is a
tyrosine kinase receptor, and the interactions are thus likely different, it
is possible that flexibilitymay be needed for structural rearrangement in
a similar fashion to bind the receptor.
An essential requirement for binding to the relaxin receptor is a con-
served RXXXRXX(I/V) motif that is presented on one face of the
B-chain helix (38). Both relaxin and relaxin-3 have this motif and have
the ability to stimulate the relaxin receptor LGR7, but relaxin-3 has a
50–100-fold lower activity (1, 15). Recent mutational studies on the
relaxin receptor LGR7 revealed a binding surface in the pleated sheet
region of the ectodomain comprising two crucial Asp-Glu pairs in the
right positions for chelating each of the relaxin active-site Arg residues
and, in addition, a cluster of hydrophobic residues equally important for
relaxin binding assumed to be clustering with the active-site Ile/Val
(38). Interestingly, the structure of H3 relaxin reveals that the C termi-
nus of the B-chain interacts with the molecular core, including the
important IleB19 of the active site. As shown in Fig. 6, this interaction
partly blocks the accessibility of IleB19 and would interfere with the
binding to LGR7. This suggests either that a conformational change, like
the detachment of the C-terminal tail proposed for insulin, is needed for
H3 relaxin to be able to interact with LGR7 or that the interaction may
be different, and this can account for the reduced activity of H3 relaxin
relative to H2 relaxin in activating LGR7. It is also apparent that PheB20,
which is presented on the same face of the B-chain helix, is highly
exposed to the solvent. As this residue is fully conserved among the
relaxin-3 family members, it is interesting to speculate that it may play
an important role in the interaction of relaxin-3 with its receptor
GPCR135. An additional important feature of the disposition of the C
terminus of the B chain is the interaction of H3 relaxin with LGR8. H2
relaxin has been demonstrated to be a high affinity ligand of LGR8, but
H3 relaxin is inactive at this receptor (15). It has been demonstrated
previously that the C terminus of the B chain in INSL3 (the endogenous
ligand of LGR8), in particular the sequence GGPRW, is essential for the
interaction of INSL3 with LGR8 (39). The tryptophan residue is essen-
tial for LGR8 activity, and this residue is present in the identical position
inH2 relaxin. This tryptophan and the entiremotif are highly conserved
in H3 relaxin, and it was a surprise when H3 relaxin was demonstrated
to have no activity at LGR8. Hence, the interaction of TrpB27 in H3
relaxin with the hydrophobic core of the molecule demonstrated in this
study may explain its lack of activity for LGR8.
Finally, anunusual but characteristic feature of the relaxinpeptide family
is that high sequence variability is seen between closely related species,
whereas distant species show high homology (5). Furthermore, the rela-
tionship between primary sequence of relaxins and their biological activity
is puzzling.Anumber ofmutational studies have provided valuable data on
the residues crucial for the biological activity of several members of the
relaxin family.However, althoughamotif foundtoberesponsible for recep-
tor binding in one hormonemay be conserved in other family members, it
does not always confer the same activity. In this study, we have shown that,
despite the family’shighlyconservedoverall fold, therearedifferences in the
tertiary structures of relaxins and that these differences, not necessarily
caused by sequence differences in the active site, may provide an explana-
tion for such observations.
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